Douglas Lane & Associates LLC Acquires 18,914 Shares of Illumina, Inc. $ILMN

Douglas Lane & Associates LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 307,609 shares of the life sciences company’s stock after buying an additional 18,914 shares during the quarter. Douglas Lane & Associates LLC owned 0.20% of Illumina worth $29,214,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Parkside Financial Bank & Trust boosted its stake in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares during the last quarter. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the period. Cullen Frost Bankers Inc. purchased a new position in Illumina in the second quarter valued at approximately $41,000. NewSquare Capital LLC grew its holdings in Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the period. Finally, Evelyn Partners Investment Management LLP increased its position in Illumina by 4,927.3% in the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after buying an additional 542 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 3.3%

Shares of Illumina stock opened at $134.78 on Friday. The company’s 50-day moving average price is $118.22 and its 200-day moving average price is $104.49. The company has a market cap of $20.59 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 2.41 and a beta of 1.44. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. Illumina’s revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ILMN shares. Evercore ISI upped their price target on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Barclays upped their price target on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $117.19.

Insider Buying and Selling at Illumina

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This represents a 4.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.